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Abstract
AMP-activated protein kinase (AMPK) is a key regulator
of cellular and body energy homeostasis. We previously
demonstrated that AMPK activation in osteoblasts increases
in vitro bone formation while deletion of the Ampka1
(Prkaa1) subunit, the dominant catalytic subunit expressed in
bone, leads to decreased bone mass in vivo. To investigate the
cause of low bone mass in the Ampka1K/Kmice, we analysed
bone formation and resorption in the tibia of these mice
by dynamic histomorphometry and determined whether
bone turnover can be stimulated in the absence of the
Ampka1 subunit. We subjected 12-week-old Ampka1C/C
and Ampka1K/K mice to ovariectomy (OVX), intermittent
PTH (iPTH) administration (80 mg/kg per day, 5 days/week)
or both OVX and iPTH hormonal challenges. Tibiae were
harvested from these mice and bone micro-architecture was
determined by micro-computed tomography. We show for
the first time that Ampka1K/K mice have a high bone
turnover at the basal level in favour of bone resorption.
While both Ampka1C/C and Ampka1K/K mice lost
bone mass after OVX, the bone loss in Ampka1K/K mice
was lower compared with controls. iPTH increased
trabecular and cortical bone indexes in both ovariectomised
Ampka1C/C and Ampka1K/K mice. However, ovariecto-
mised Ampka1K/K mice showed a smaller increase in bone
parameters in response to iPTH compared with Ampka1C/C
mice. By contrast, non-ovariectomised Ampka1K/K mice
responded better to iPTH treatment than non-ovariecto-
mised Ampka1C/C mice. Overall, these data demonstrate
that Ampka1K/K mice are less affected by changes in bone
turnover induced by OVX but respond better to the anabolic
challenge induced by iPTH. These results suggest that
AMPKa1 activation may play a role in the hormonal
regulation of bone remodelling.
Journal of Endocrinology (2012) 214, 349–358
Introduction
AMP-activated protein kinase (AMPK) is a sensor and
regulator of energy homeostasis not only at the cellular
level but also at the whole-body level where it mediates the
central and peripheral effects of many hormones on the
metabolisms of appetite, fat and glucose (Minokoshi et al.
2002, Yamauchi et al. 2002, Andersson et al. 2004, Banerjee
et al. 2004, Minokoshi et al. 2004, Han et al. 2005, Kola et al.
2005, Yamauchi et al. 2008 and for reviews see Hardie et al.
2006, Kola et al. 2006 and Lage et al. 2008). It is a highly
conserved, ubiquitously expressed serine/threonine hetero-
trimeric protein kinase consisting of a catalytic a subunit
and regulatory b and g subunits, all of which have several
isoforms with differential tissue-specific expression patterns
(Hardie et al. 2006, Kola et al. 2006, Steinberg & Kemp 2009,
Viollet et al. 2010, Hardie et al. 2011). AMPK senses the
AMP/ATP ratio within the cell and is activated in response
to environmental or nutritional stress factors that deplete
intracellular ATP levels (Hardie et al. 2006, Hardie 2008,
Steinberg & Kemp 2009). AMP binding activates AMPK by
two mechanisms, phosphorylation of the Thr-172 residue in
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the a subunit by upstream kinases and inhibition of
dephosphorylation of Thr-172 by phosphatases (Hawley
et al. 1996, 2003, 2005, Xiao et al. 2011). Once activated,
it switches on catabolic pathways that generate ATP and
switches off anabolic pathways that consume ATP.
In the last few years, several in vitro and in vivo studies have
established that the AMPK signalling pathway could also play
a role in bone physiology (Kanazawa et al. 2008, 2009, Kasai
et al. 2009, Lee et al. 2010, Molinuevo et al. 2010, Quinn et al.
2010, Shah et al. 2010, Zhen et al. 2010, Jang et al. 2011a,b,
Mai et al. 2011, Wu et al. 2011). We demonstrated that the
AMPKa1 subunit is the dominant catalytic isoform expressed
in bone and that AMPK activators stimulate in vitro bone
nodule formation (Shah et al. 2010). Several other studies
have confirmed that the two main AMPK activators,
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR)
and metformin, are osteogenic in vitro. They stimulate pro-
liferation, differentiation and mineralisation of MC3T3-E1
osteoblastic cells (Kanazawa et al. 2008, 2009, Jang et al.
2011a,b, Mai et al. 2011), primary osteoblasts (Shah et al. 2010,
Zhen et al. 2010) and bone marrow progenitor cells
(Molinuevo et al. 2010, Wu et al. 2011). However, it was
also reported that osteoblast differentiation is functionally
associated with decreased AMPK activity (Kasai et al. 2009).
The relationship between AMPK activation and bone
resorption is also unclear. Activation of AMPK was shown
to inhibit osteoclast formation and bone resorption in vitro,
AMPK acting as a negative regulator of RANKL (Lee et al.
2010). By contrast, in vivo studies have shown that AICAR
stimulates bone loss and bone turnover in male mice (Quinn
et al. 2010). The evidence for a role of AMPK signalling in
the regulation of bone mass is best supported by genetic studies.
Our work has shown that Ampka1 (Prkaa1) knockout
(Ampka1K/K) mice have a very low bone mass compared
with the WT (Ampka1C/C) mice, both cortical and trabecular
bone compartments being smaller in the Ampka1K/K mice
(Shah et al. 2010). Similarly, Quinn et al. (2010) showed that
germline deletions of either the AMPKb1 or b2 subunit
resulted in reduced trabecular bone density and mass.
The underlying mechanism for the low bone mass in
Ampka1K/K mice and the exact role of AMPK in bone
remodelling in vivo have not yet been investigated. Bone
remodelling occurs constantly at multiple locations within the
skeleton and bone needs to balance energy in response to
nutrient availability with growth and turnover. To address the
role of AMPK in bone turnover, we subjected Ampka1K/K
and Ampka1C/C mice to two types of hormonal challenges
that increase bone turnover, ovariectomy (OVX) that induces
a negative bone balance and intermittent PTH (iPTH)
treatment that is anabolic, and examined their effects on
bone architecture in these mice. We show that Ampka1K/K
mice have high bone turnover at basal level and that bone
turnover in Ampka1K/K mice is altered in response to OVX
and iPTH, suggesting that AMPK activation may modulate
the hormonal regulation of bone remodelling.
Materials and Methods
Animals
Ampka1 knockout mice were generously provided by
Dr Benoit Viollet (INSERM, U1016, Paris, France) and
were generated as described previously ( Jorgensen et al.
2004). Ampka1C/C and Ampka1K/K mice in C57BL/6!
129/Sv mixed background were used. All procedures were
performed in accordance with the principles and guidelines
established by the European Convention for the Protection
of Laboratory Animals. All mice were maintained under a
controlled temperature (21 8C) and lighting with 12 h
light:12 h darkness cycle and received a standard mouse
chow diet and water ad libitum. The knockout mice do not
show any obvious metabolic phenotypes and their body
weight was unaffected (Jorgensen et al. 2004).
Hormonal challenges
Three independent experiments were carried out to
determine the response of bone to hormonal challenges
in Ampka1 knockout mice. In study 1, 12-week-old
Ampka1C/C and Ampka1K/K mice (nZ7/group) were
either ovariectomised or sham operated. Tibiae were
collected from these mice 6 weeks after OVX for micro-
computed tomography (micro-CT) analysis. For measure-
ment of dynamic bone formation parameters, mice in this
study were i.p. injected with calcein (Sigma–Aldrich) and
alizarin red complexone (Sigma–Aldrich), at days 6 and 3,
respectively, before killing. For study 2, 12-week-old
Ampka1C/C and Ampka1K/K mice (nZ8/group) were
all ovariectomised and immediately treated for 4 weeks
with s.c. injection of either 80 mg/kg per day, 5 days/week,
PTH (human PTH (1–34; Bachem, Inc., Torrance, CA,
USA) dissolved in 1 mM HCl containing 0.2% BSA)
or saline. For study 3, 12-week-old Ampka1C/C and
Ampka1K/K mice (nZ10–11/group) were treated with
s.c. injection of either 80 mg/kg per day, 5 days/week, iPTH
or saline. For all mice, body weight was measured at
the beginning of week 13 (i.e. on day of sham operation,
OVX or at the beginning of iPTH treatment) and at
the end of the experiment. Left and right tibiae were
harvested from these mice for micro-CT (studies 1, 2
and 3) and bone histomorphometric analyses (study 1)
respectively. Femora were collected for western blot and
RT-PCR analyses.
Histomorphometry analysis of tibia
Right tibia from sham-operatedAmpka1C/C andAmpka1K/K
mice from study 1 were fixed in 10% neutral-buffered
formalin for 24–72 h, dehydrated and embedded in pure
methyl methacrylate at low temperature to preserve
enzymatic activity (Chappard et al. 1987). Unstained
8 mm-thick sections were used for fluorescence
J JEYABALAN and others . Bone remodelling in Ampka1K/K mice350
Journal of Endocrinology (2012) 214, 349–358 www.endocrinology-journals.org
microscopy to assess mineral apposition rate (MAR, mm/day).
Mineralising surfaces were expressed as doubleChalf single
labelled surfaces per bone surfaces (MS/BS, %) and the bone
formation rate was calculated as MS/BS!MAR (BFR/BS,
mm3/mm2 per day; Chavassieux et al. 1997). Alternatively,
sections were stained for tartrate-resistant acid phosphatase
(TRAP; Leucognost SP, Merck) and counterstained with
Mayer’s hemalum solution. Goldner’s trichrome staining was
performed to determine adipocyte number per tissue area.
Histomorphometric parameters were measured on the trabe-
cular bone of the metaphysis, on a region of interest consisting
of 2 mm width below the growth plate. Measurements were
performed using an Image Analysis Software (Bone, Explora
Nova, La Rochelle, France). Histomorphometric parameters
were reported in accordance with the ASBMR Committee
nomenclature (Parfitt et al. 1987).
Micro-CT analysis of tibia
Left tibia was fixed in 10% neural-buffered formalin for
24–72 h and stored in 70% ethanol at 4 8C. They were
scanned with high-resolution (5 mm pixel size) micro-CT
(Skyscan 1172, Kontich, Belgium), as described previously
(Shah et al. 2010). The whole tibia was reconstructed using
NRecon v.1.4.4.0 (Skyscan) and bone histomorphometric
analyses in 2- and 3-dimensions (2D and 3D) were performed
by Skyscan Software (CT-Analyser v.1.5.1.3). For the analysis
of trabecular bone, the cortical shell was excluded by
operator-drawn regions of interest and 3D algorithms were
used to determine the relevant parameters that included
bone volume (BV) percentage (BV/tissue volume (TV), %),
direct trabecular thickness (Tb.Th) and spacing, trabecular
number (Tb.N), structure model index (SMI), trabecular
bone pattern factor (TBPf) and the degree of anisotropy (DA).
Analysis of cortical bone was performed using a 0.49 mm
long segment (or 100 tomograms) at 37% of the tibias’ length
from the proximal end. For analysis of the cortical bone
compartment, 2D computation was used and parameters were
determined for each one of the 100 tomograms and then
averaged. They included periosteal perimeter (Ps.Pm),
endosteal perimeter (Ec.Pm) and cortical thickness (Ct.Th).
RNA extraction and RT-PCR analysis
Total RNA was isolated from femora and femoral muscles
of Ampka1C/C and Ampka1K/K mice and amplified
using subunit-specific primers, as described previously
(Shah et al. 2010).
Protein extraction and western blot analysis
For the isolation of total proteins, right and left femora from
Ampka1C/C and Ampka1K/K mice were carefully dissected,
all their surrounding musculature removed leaving the
periosteum intact. The cartilaginous ends of the bones
were separated and the remaining femoral shafts were flushed
with PBS to remove the marrow. The femoral shafts were then
snap-frozen and pulverised under liquid nitrogen using a mortar
andpestle and then lysed in colddenaturing lysis buffer (2% SDS,
2 M urea, 8% sucrose, 20 mM sodium glycerophosphate, 1 mM
sodium fluoride, and 5 mM sodium orthovanadate). Proteins
were denatured by boiling for 5 min and concentrations were
determined by BCA protein assay. Two micrograms of proteins
were size fractionated using SDS–PAGE and electrotransferred
onto Protran nitrocellulose membranes (Schliecher and
Schuell, Dassel, Germany). Membranes were blocked for 1 h
in 0.2% (w/v) I-block (Topix, Bedford, MA, USA), before
being incubated with primary antibodies. The blots were
incubated overnight at 4 8C with antibodies against total
AMPKa1/2 (tAMPK a1/2, rabbit), phospho-(Thr-172)-
AMPKa1/2 (pAMPKa1/2, rabbit) (New England Biolabs,
Hitchin, UK) and b-actin (goat) (Dako, Ely, UK), all added at a
1:1000 dilution. The following secondary antibodies were used:
goat anti-rabbit (New England Biolabs) against tAMPK and
pAMPKa1/2 and rabbit anti-goat (Dako) against b-actin
antibody, both at 1:2500 dilution at room temperature
for 1 h. Proteins were visualised using the enhanced chemi-
luminescence (ECL) detection system (GE Healthcare UK Ltd.,
Little Chalfont, UK). The intensity of the specific bands was
quantified by densitometry using Image J Software.
Statistical analysis
The results are presented as meanGS.E.M. Comparisons
between groups for all the data were performed using
nonparametric Mann–Whitney U test. Differences were
considered statistically significant at P!0.05. All statistical
analyses were performed using GraphPad Prism Software
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
Female Ampka1K/K mice have decreased bone mass and
increased bone remodelling
While our previous analysis of bone architecture inAmpka1K/K
mice was done in males (Shah et al. 2010), we confirmed
with the present experiments that female Ampka1K/K mice
have a similar low bone mass phenotype compared with
Ampka1C/C mice. The micro-CT measurements of
trabecular and cortical parameters in tibia of non-OVX
adult female mice (Fig. 1A and B) showed that the
Ampka1K/K mice had significantly lower BV/TV, Tb.N
and Ct.Th compared with Ampka1C/C mice. Ampka1K/K
mice also showed a significant increase in SMI, a
parameter reflecting trabecular shape, plate to rod elements
(Ampka1C/C, 1.19G0.15 vs Ampka1K/K, 1.69G0.07;
P!0.05), compared with Ampka1C/C mice. There were
statistically non-significant increases in trabecular separation
(Ampka1C/C, 0.30G0.05 mm vs Ampka1K/K, 0.47
G0.05 mm; PZ0.073) and TBPf (Fig. 1A) in Ampka1K/K
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mice, suggesting poor trabecular interconnection. The DA
reflecting trabecular structure (Ampka1C/C, 1.64G0.10 vs
Ampka1K/K, 2.57G0.90; PZ1.000) and Ps.Pm and Ec.Pm
(Fig. 1B) were not significantly different between the
Ampka1C/C and Ampka1K/K mice. These changes in the
trabecular and cortical parameters of female Ampka1K/K
mice are similar to those observed in male Ampka1K/K mice
(Shah et al. 2010). The trabecular architecture in Ampka1K/K
mice, characterised by increased SMI, trabecular separation
and TBPf and lower BV/TV are similar to the changes seen
during ageing and osteoporosis, suggesting an altered bone
remodelling at basal level in these mice. To determine the
cause of the low bone mass in Ampka1K/Kmice and whether
bone remodelling is affected in these mice at basal level, we
examined bone formation and resorption in the tibia of those
mice, using bone histomorphometry. Analysis of BFR using
double fluorescence labelling showed that the Ampka1K/K
mice had a higher BFR than Ampka1C/Cmice (Fig. 2A), but
this was not significant (PZ0.095). The percentage of
TRAP-positive surfaces (osteoclasts surfaces) was signifi-
cantly higher in the Ampka1K/K mice compared with
Ampka1C/C mice (Fig. 2B). These results suggest that the
Ampka1K/K mice have a higher bone turnover compared
with their Ampka1C/C littermates in favour of bone
resorption. In addition, the Ampka1K/K mice had twice
the number of adipocytes than the Ampka1C/C mice within
the bone marrow but, due to a large variation between
animals, the difference was not significant (Fig. 2C).
Figure 1 Effect of ovariectomy (OVX) on trabecular and cortical
bone parameters in tibia of Ampka1C/C and Ampka1K/K mice.
(A) Trabecular bone parameters in Ampka1C/C and Ampka1K/K
mice that have undergone OVX or sham operation. (B) Cortical
bone parameters in Ampka1C/C and Ampka1K/K mice subjected
to OVX or sham operation. Values are meanGS.E.M. of nZ7
mice/group, *P!0.05, **P!0.01.
Figure 2 Dynamic bone histomorphometry analyses in
Ampka1C/C and Ampka1K/K mice. (A) BFR, (B) percentage of
TRAP surfaces and (C) number of adipocytes per tissue area in
16-week-old Ampka1C/C and Ampka1K/K mice. Values are
meanGS.E.M. of nZ7 mice/group, **P!0.01.
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Ovariectomy (OVX) induces bone loss in Ampka1C/C and
Ampka1K/K mice
To investigate the skeletal response of Ampka1K/K mice to
OVX, known to stimulate bone remodelling, OVX or sham
operations were performed in Ampka1C/C and Ampka1K/K
mice. All the mice from these groups have gained weight
throughout the treatment period. However, comparison of
weight changes (from the day of sham or OVX operation
to day of sacrifice, i.e. over the 6-week period) between the
groups did not detect any statistically significant differences
(sham-Ampka1C/C, 1.37G0.61 g vs OVX–Ampka1C/C,
1.66G0.42 g; sham-Ampka1K/K, 1.76G0.25 g vs OVX–
Ampka1K/K, 1.54G0.30 g). In addition, there was no
significant difference in weight change between sham-
Ampka1C/C and sham-Ampka1K/K mice. Tibial bone
length was also not significantly different betweenAmpka1C/C
or Ampka1K/K mice (data not shown).
As expected, OVX induced bone loss in Ampka1C/C
mice. These mice showed a significant decrease in BV/TV
after OVX (Fig. 1A). Tb.N (PZ0.097) and thickness
(PZ0.073) were also decreased in the Ampka1C/C mice
after OVX, while TBPf was increased (PZ0.165), although
these parameters were not statistically significant (Fig. 1A).
Analysis of cortical parameters demonstrated a significant
increase in Ec.Pm and Ps.Pm in Ampka1C/C mice after
OVX (Fig. 1B). By contrast, Ct.Th was significantly
decreased after OVX in these mice (Fig. 1B).
Ovariectomy also induced alterations in both the trabecular
and cortical bones in the Ampka1K/K mice, but the effects
were moderate, indicating that the bone response to OVX
in these mice is attenuated (Fig. 1). Ampka1K/K mice
showed a significant increase in TBPf, but there were non-
statistically significant decreases in BV/TV, Tb.N and
thickness after OVX in these mice (Fig. 1A). Cortical
parameters were not significantly affected in the Ampka1K/K
mice after OVX (Fig. 1B).
iPTH increases bone formation in ovariectomised Ampka1C/C
and Ampka1K/K mice
To determine whether PTH treatment overcomes the bone
loss induced by OVX in Ampka1C/C and Ampka1K/K
mice, those mice were ovariectomised and then treated with
iPTH or saline for 4 weeks. There was no difference in weight
due to iPTH treatment in the ovariectomised Ampka1C/C
and Ampka1K/K mice (data not shown). Our results
demonstrate that iPTH treatment alters trabecular and
cortical bone indexes in both OVX–Ampka1C/C and
OVX–Ampka1K/K mice (Fig. 3).
In OVX–Ampka1C/C mice, iPTH induced a significant
increase in BV/TV and Tb.N and a significant decrease in
TBPf (Fig. 3A), trabecular separation (Saline OVX–
Ampka1C/C, 0.46G0.03 mm vs iPTH OVX–Ampka1C/C,
0.20G0.01 mm; P!0.0005) and SMI (Saline OVX–
Ampka1C/C, 2.37G0.04 vs iPTH OVX–Ampka1C/C,
1.38G0.09; P!0.0005). In the cortical compartment,
Ps.Pm and Ec.Pm were significantly increased as a result of
iPTH treatment in the OVX–Ampka1C/C mice, while
Ct.Th was not affected (Fig. 3B).
Similarly, in OVX–Ampka1K/K mice, iPTH signifi-
cantly increased BV/TV and Tb.N, but significantly
decreased Tb.Th (Fig. 3A), separation (Saline OVX–
Ampka1K/K, 0.29G0.01 mm vs iPTH OVX–Ampka1K/K,
0.23G0.01 mm; P!0.05) and SMI (Saline OVX–
Ampka1K/K, 2.01G0.05 vs iPTH OVX–Ampka1K/K,
1.53G0.13; P!0.05). Within the cortical compartment of
these mice, Ps.Pm was also significantly increased by iPTH
Figure 3 Effect of 4 weeks of iPTH treatment on trabecular and
cortical bone parameters in tibia of ovariectomised Ampka1C/C
and Ampka1K/K mice. (A) Trabecular bone parameters in
ovariectomised Ampka1C/C (OVX–Ampka1C/C) and Ampka1K/K
(OVX–Ampka1K/K) mice that have been treated with iPTH or
saline. (B) Cortical bone parameters in OVX–Ampka1C/C and
OVX–Ampka1K/K mice subjected to iPTH or saline treatment.
Values are meanGS.E.M. of nZ8 mice/group, *P!0.05, **P!0.01,
***P!0.001.
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treatment but not the other parameters (Fig. 3B). Our results
illustrate that the ovariectomised Ampka1K/K mice have an
attenuated response to iPTH treatment compared with
Ampka1C/C mice.
iPTH increases bone formation in Ampka1C/C and
Ampka1K/K mice
We then analysed the effect of iPTH in non-ovariectomised
Ampka1C/C and Ampka1K/K mice. Four weeks of iPTH
treatment in the non-ovariectomised Ampka1C/C mice
induced mild increases in bone formation in the trabecular
and cortical compartments (Fig. 4). Within the trabecular
compartment, the only statistically significant change
induced by iPTH was a decrease in DA (saline-Ampka1C/C,
1.81G0.04 vs iPTH-Ampka1C/C, 1.69G0.04; P!0.05).
There were non-significant increases in BV/TV (PZ0.057),
Tb.N (PZ0.076) and thickness (PZ0.066; Fig. 4A). iPTH
also induced a significant increase in Ct.Th in the
Ampka1C/C mice (Fig. 4B), while the other cortical
bone parameters were not significantly affected. By contrast,
in the Ampka1K/Kmice, iPTH induced a significant increase
in BV/TV and Tb.N and a significant decrease in
TBPf (Fig. 4A), trabecular separation (saline-Ampka1K/K,
0.25G0.01 mm vs iPTH-Ampka1K/K, 0.19G0.01 mm;
P!0.005), SMI (saline-Ampka1K/K, 2.07G0.08 vs
iPTH-Ampka1K/K, 1.12G0.18; P!0.0005) and DA
(saline-Ampka1K/K, 1.98G0.05 vs iPTH-Ampka1K/K,
1.59G0.07; P!0.005). In the cortical compartment, it
significantly increased Ec.Pm but had no effect on the
other parameters (Fig. 4B). Surprisingly, in this experiment,
Ct.Th was not decreased in the saline Ampka1K/K mice
compared with Ampka1C/C mice, in contrast to Fig. 1 and
our previous results (Shah et al. 2010).
The comparison of changes in trabecular and cortical
parameters due to iPTH treatment between Ampka1C/C and
Ampka1K/Kmice shows that PTH induces a greater increase
in bone in the non-ovariectomised Ampka1K/K mice.
iPTH induces AMPKa phosphorylation in Ampka1C/C mice
To determine whether iPTH treatment could affect bone
AMPK activity, AMPKa1/2 subunit phosphorylation was
determined by western blot analysis of proteins extracted
from femora of mice from study 2 treated with saline or
iPTH. The antibodies we used against phosphorylated
AMPKa and total AMPKa do not differentiate between the
a1 and a2 subunits. Our western blot analysis showed that
iPTH induced a significant increase in pAMPKa1/2 levels in
Ampka1C/C mice but not in Ampka1K/K mice (Fig. 5Ai
and ii). We previously showed that there is a very low level
expression of a2 subunit in bone at basal conditions (Shah
et al. 2010). To confirm that the absence of a1 transcript in
the Ampka1K/K mice does not induce a compensatory
increase in a2 expression in bone, we examined the
expression of a subunits in bones from Ampka1K/K mice
and showed that there was no overexpression of a2 in
the bones of these mice (Fig. 5B).
Discussion
We show in this study that the low bone mass observed in
male Ampka1K/Kmice is also observed in femaleAmpka1K/K
mice and is due to an increase in bone formation and
resorption with an imbalance in favour of resorption. In
addition, our results reveal that bone turnover induced by
OVX and iPTH hormonal challenges is moderately reduced
in the Ampka1 subunit knockout mice. However, the skeletal
responses to OVX and iPTH in these mice were different
Figure 4 Effect of 4 weeks of iPTH treatment on trabecular and
cortical bone parameters in tibia of Ampka1C/C and Ampka1K/K
mice. (A) Trabecular bone parameters in Ampka1C/C and
Ampka1K/Kmice that have been treated with either iPTH or saline
for 4 weeks. (B) Cortical bone parameters in Ampka1C/C and
Ampka1K/K mice treated with iPTH or saline for 4 weeks. Values
are meanGS.E.M. of nZ10–11 mice/group, *P!0.05, ***P!0.001.
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from their WT littermate controls, suggesting that AMPK
activation mediates the effects of these hormones on bone
turnover.
The increased BFR and resorption surfaces in the
Ampka1K/K mice suggest increased bone remodelling.
This accelerated bone turnover in favour of bone resorption
could explain their low bone mass at basal level. Interestingly,
deletion of AMPKb subunits in mice also reduced bone mass
and the authors did not observe any reduction in osteoblast or
osteoclast numbers in these mice, suggesting that the low
bone mass observed in Ampkb1 and 2 knockout mice could
be due to changes in bone cellular functions (Quinn et al.
2010). Our results, although not statistically significant, show
an increase in BFR and MS, reflecting active bone formation,
which could be due to an increase in the birth of new
remodelling units and/or an increase in the lifespan of these
remodelling units. At the cellular level, this could be the result
of an enhanced differentiation of osteoprogenitors into
mature osteoblasts or an increased lifespan of osteoblasts.
This increase in bone formation was an unexpected finding as
several in vitro studies indicate that AMPK activation
stimulates bone formation (Kanazawa et al. 2008, 2009,
Molinuevo et al. 2010, Shah et al. 2010, Jang et al. 2011a,b,
Mai et al. 2011, Wu et al. 2011). We also show in this paper
a trend towards an increase in marrow adipocyte numbers
in bones of Ampka1K/K mice, which could suggest a
potential interaction between AMPK signalling in fat and
bone, and this will need to be further investigated. Our results
indicate that bone resorption is increased in Ampka1K/K
mice, suggesting that AMPKa1 activation inhibits bone
resorption. Indeed, it has been shown that AMPK acts as a
negative regulator of RANKL in bone marrow macrophages,
and inhibition of AMPK increases RANKL-dependent
formation of TRAP-positive multinucleated cells and
bone resorption area (Lee et al. 2010). This could therefore
explain the increase in percentage of TRAP surfaces in
Ampka1K/K mice.
To clarify whether changes in basal bone cellular activities
in Ampka1K/K mice affect their responses to changes in
bone turnover, we first submitted these mice to OVX.
Loss of bone mass, trabecular thinning and increased
trabecular separation are general features of bone after OVX
(Parfitt et al. 1987, Compston et al. 1989). This is due to
increased bone resorption, which exceeds bone formation
at the initial stages (Lambers et al. 2012). Consistent with
this, we observed deteriorated trabecular bone architecture in
the Ampka1C/C mice after OVX. Furthermore, OVX
caused endosteal bone resorption and periosteal bone
apposition in these mice, which is consistent with the
known effect of OVX on cortical bone architecture (Turner
et al. 1987a,b). Weight gain is typically observed after OVX
in rats and in humans after menopause (Lobo 2008, Tezval
et al. 2011a). Although all mice gained weight during the
6-week experimental period, OVX did not induce significant
weight gain in both the Ampka1C/C and Ampka1K/Kmice.
Body weight gain after OVX in mice is not always observed
and may depend on the genetic background, as previously
reported (Andersson et al. 2001, Bouxsein et al. 2005, Li et al.
2005, Iwaniec et al. 2006).
Our results illustrate that Ampka1K/K mice, similar to
Ampka1C/C mice, can lose bone after OVX, although this
bone loss was moderate compared with Ampka1C/C mice.
This suggests that AMPKa1 is likely to play a role in bone
resorption and remodelling induced by OVX. As bone mass is
already very low at basal levels in the Ampka1K/Kmice, there
may be a protective mechanism to reduce the level of bone
loss induced by OVX and to preserve the bone architecture
without causing deleterious effects. One possibility for this
mechanism could be the fact that there is less surface area
for bone resorption. A study investigating OVX-induced
bone loss in different inbred mouse strains revealed indeed
that strains with low basal trabecular bone mass lose less
bone compared with mice with high basal bone mass
(Bouxsein et al. 2005). Alternatively, as bone remodelling is
already very high in Ampka1K/K mice, they may be less
sensitive to an increase in bone remodelling induced by
oestrogen withdrawal.
Figure 5 Effect of iPTH treatment on AMPKa1/2 phosphorylation
in bone of ovariectomised Ampka1C/C and Ampka1K/K mice.
(A, i) Western blot analysis of pAMPKa1/2 and tAMPKa1/2. Proteins
were extracted from femora of 16-week-old OVX–Ampka1C/C and
OVX–Ampka1K/K mice from study 2 and probed with polyclonal
antibodies directed against pAMPKa1/2, tAMPKa1/2 and b-actin.
Representative immunoblots are shown, which were repeated three
times with similar results. (ii) Graph showing the ratio of pAMPK
a1/2 to tAMPKa1/2 relative to b-actin determined by densitometry
analysis of western blot data using Image J Software. Proteins were
extracted from femora of two mice per group and western blot
analyses were carried out in triplicates. Values are meanGS.E.M.,
*P!0.05. (B) RT-PCR analysis of RNA extracted from femora of
Ampka1C/C and Ampka1K/K mice showing differential subunit
expression pattern. Expression pattern of AMPK subunits in femoral
muscle from Ampka1C/C mice was carried as a control.
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Intermittent administration of PTH is known to increase
bone mass and improve bone architecture (Iida-Klein et al.
2002, Jiang et al. 2003, Brouwers et al. 2009, Recker et al.
2009). At the cellular level, iPTH has been shown to increase
bone remodelling (Fox et al. 2006, Wade-Gueye et al. 2010)
with bone formation exceeding resorption. To understand
the bone responses of Ampka1K/K mice to anabolic (iPTH)
stimuli, we first subjected ovariectomised Ampka1C/C
and Ampka1K/K mice to iPTH treatment for 4 weeks
(study 2). Our results confirm previous studies showing that
iPTH (1–34) can increase bone formation in ovariectomised
rodents (Alexander et al. 2001, Fox et al. 2006, Wade-Gueye
et al. 2010, Tezval et al. 2011a). We show that similar to
OVX–Ampka1C/C mice, OVX–Ampka1K/K mice have an
increase in trabecular BVand number as well as an augmented
cortical bone mass in response to iPTH, confirming that
osteoblast function is not severely affected in these
Ampka1K/Kmice. OVX–Ampka1K/Kmice were, however,
less affected than OVX–Ampka1C/C mice by the changes
in bone turnover induced by iPTH, possibly because they
lost less bone after OVX than their WT controls. We
indeed found in this study that the trabecular bone mass in
OVX–Ampka1K/K mice was higher than that of OVX–
Ampka1C/C mice (Fig. 3), which contrasts with our first
study (Fig. 1) where OVX–Ampka1K/K mice had lower
trabecular bone mass than OVX–Ampka1C/C mice. This
suggests that the Ampka1K/K mice in study 2 did not lose as
much bone mass after OVX as those in study 1. This
discrepancy in the amount of bone loss after OVX between
our two studies may be due to the time after OVX. In study 1,
bone mass was determined 6 weeks after OVX while in
study 2 it was investigated after 4 weeks, and there are studies
supporting a time-dependent bone loss after OVX (Li et al.
2005, Iwaniec et al. 2006). It is also possible that the absence
of AMPKa1 may have contributed to this delay in bone
loss after OVX in the Ampka1K/K mice.
To further investigate whether Ampka1K/K mice
responded to the sole anabolic effect of iPTH, non-
ovariectomised Ampka1C/C and Ampka1K/K mice were
treated with iPTH for 4 weeks (study 3). In non-
ovariectomised Ampka1C/C mice, iPTH induced a smaller
increase in bone mass compared with mice that were
ovariectomised, suggesting that OVX enhances the anabolic
effect of iPTH on bone mass, as previously demonstrated
(Andersson et al. 2001, Tezval et al. 2011b). By contrast, iPTH
elicited a larger increase in bone mass in non-ovariectomised
Ampka1K/K mice compared with Ampka1C/C mice,
possibly due to the low basal level of bone mass in these
mice, enhancing the effect of iPTH. Interestingly, the
comparison of the percentage of increased bone mass induced
by iPTH in OVX–Ampka1K/K mice (study 2) and non-
OVX–Ampka1K/K mice (study 3) showed that it is similar,
in contrast to Ampka1C/C mice where there is about a
tenfold decrease in the response to iPTH in non-OVX mice.
Our data suggest that the presence of the AMPKa1
subunit, and consequently AMPK activation in bone, is not
essential for bone turnover but may contribute to the
modulation of this process. We previously showed that the
a2 subunit, in contrast to other tissues (Stapleton et al. 1996,
Quinn et al. 2009, Shah et al. 2010), is not highly expressed in
bone (Quinn et al. 2010, Shah et al. 2010). Furthermore, our
results demonstrate that there is no compensatory up-regula-
tion of a2 in bones of Ampka1K/K mice. This is in contrast
to the demonstration of an up-regulation of a2 in the soleus
and extensor digitorum muscle in the Ampka1K/K mice
( Jorgensen et al. 2004). We cannot exclude, however, that this
up-regulation of a2 in muscle and possibly in other
tissues in these mice may have indirectly affected bone
( Jorgensen et al. 2004).
As our study was performed with Ampka1K/K mice that
are conventional whole-body knockout, we cannot exclude
that the effects of the deletion of the a1 subunit observed in
bone may be the result of indirect effects of AMPK deletion
in other tissues. Ampka1K/K mice have been reported to
have significantly reduced inguinal and epididymal fat
weights compared with Ampka1C/C mice and a tendency
for lower body weights (Daval et al. 2005), although this was
not observed in our study or in other studies ( Jorgensen et al.
2004, Viollet et al. 2009). No other metabolic phenotype was
reported in these Ampka1K/K mice and these mice have no
changes in oestrogen levels. It is, however, unknown whether
PTH levels are altered in these mice.
While the hormonal regulation of AMPK activation is well
characterised in several tissues (Xue & Kahn 2006, Dzamko &
Steinberg 2009, Lim et al. 2010), it has not been extensively
studied in bone. Our previous work has shown that AMPK
activity in bone cells could be regulated by the same
hormones that regulate food intake and energy expenditure
through AMPK activation in the brain and peripheral tissues
(Shah et al. 2010). While our preliminary data in the
osteoblastic cell line UMR-106 have shown no effect of
oestrogen on AMPK activation (data not shown), our results
show for the first time that iPTH increased the level of
pAMPKa1/2 in vivo in the ovariectomised Ampka1C/C
mice, suggesting that PTH may activate AMPK signalling
in bone, although this signalling pathway does not seem
essential for the effect of PTH on bone formation.
Further studies must, however, be carried out to elucidate
downstream pathways and mechanism of action. PTH
also induced a non-significant effect on phosphorylation
of AMPKa1/2 in the Ampka1K/K mice, likely due to the
phosphorylation of the a2 subunit, expressed at very low
levels in bone.
In conclusion, we demonstrate that Ampka1K/K
mice have an increased bone turnover compared with
Ampka1C/C mice and can increase and decrease bone mass
in response to anabolic and catabolic hormonal challenges,
although these responses are modified. Taken together,
our results indicate that AMPKa1 activity is not essential
for bone turnover but may contribute to the regulation of
bone remodelling.
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